Health system pharmacies manage incredibly complicated clinical, distributive, and supply chain systems, and it is critical for pharmacy to understand and effectively manage the costs attributed to the medication use process while optimizing patient safety and regulatory compliance. InPharmics currently serves more than 150 hospitals with tools that analyze drug cost by patient diagnosis, thereby supporting pharmacy’s clinical activities while helping to optimize supply chain performance and comply with drug pedigree regulations.
“InPharmics goes beyond purchasing data to deliver analytics at the patient level. Our pharmacists use web-based tools to create and maintain data linkages across the health system’s multiple information platforms. As a result, pharmacy has visibility to its cost at every point in the medication use process,” said Bobby Parker, founder of InPharmics.
Omnicell Performance Center combines enterprise software solutions with ongoing expert services to proactively monitor pharmacy operations and deliver actionable insights for improved operational efficiency, regulatory compliance, and patient outcomes.
“Pharmacy leaders face significant pressures to balance cost, quality, and compliance across an increasingly broad and more complex healthcare landscape,” said Nhat Ngo, executive vice president, strategy and business development at Omnicell. “The InPharmics solution adds clinical and compliance analytics to the Performance Center offering, positioning Omnicell as the partner of choice for health systems looking to drive improvement across all facets of medication management.”
Financial details on the acquisition are not being disclosed at this time. Omnicell expects the transaction will be immaterial and does not expect it to impact Omnicell’s previously communicated 2017 financial guidance.
InPharmics is the premier source for end-to-end medication use process cost analytics and Drug Supply Chain Security Act compliance systems specifically designed for acute care hospital pharmacies
1.jpg)
